RE:RE:RE:RE:RE:Scenarios and speculationAs ONCY has been demonstrating for Pfizer/Roche/ Incyte/ etc. to enable these Big Pharma companaies to effect a successful immune checkpoint inhibitor [anti-PD-(L)1] program .. " a ... differentiated value, e.g. by targeting sub-populations with high unmet need and by ‘guaranteeing’ positive patient outcomes, for which diagnostic and predictive biomarkers are essential " (to differentiate their ICIs from that of Merck's Keytruda) - according to MARKUS GORES Vice President, EMEA Thought Leadership, IQVIA.
"This level of unmet need combined with the potential of PD-1/PD-L1 therapies to expand into earlier settings, including neo-adjuvant, as well as opportunities to enter new indications, is fuelling frantic development activity."
As ONCY has also demonstrated and highlighted by IQVIA report .... "There is a plausible rationale for exploring combinations to overcome resistance and achieve a deep and durable response, including stimulating a stronger T-cell response, e.g. by blocking other inhibitory checkpoints; the direct modification of tumour immunogenicity, e.g. via chemotherapy, radiotherapy or oncolytic viruses; or a multi-pathway attack using other targeted therapies, e.g. VEGF or PARP inhibitors."